Canada approves once-monthly Actonel treatment
This article was originally published in Scrip
Executive Summary
Health Canada has approved Sanofi-Aventis and Procter & Gamble's bisphosphonate Actonel 150mg (risedronate sodium), for the once-monthly treatment of postmenopausal osteoporosis.